BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. The company's lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge's preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/13/24	$170,000,000	Series D	Amgen Ventures Andreessen Horowitz Bio+Health Cormorant Asset Management Longitude Capital OrbiMed Advisors Osage University Partners Pivotal bioVenture Partners RA Capital RTW Investments Sands Capital Sofinnova Investments SV Health Investors	undisclosed